Search - tctmd.com

Displaying 21 - 40 of 67

Sort: Relevancy | Date

$Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)$

Presentation ACC 2024

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Presenter: Rasha K. Al-Lamee

April 08, 2024

Presentation ACC 2024

Comparison of IVUS-guided vs. Angiography-guided Angioplasty for the Outcomes of DCB in the Treatment of Femoropopliteal Artery Disease

Presenter: Young-Guk Ko

April 08, 2024

Presentation ACC 2024

A Selective Aldose Reductase Inhibitor for the Treatment of Diabetic Cardiomyopathy

Presenter: James L. Januzzi Jr

April 08, 2024

News Conference News ACC 2024

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Yael L. Maxwell

April 07, 2024

Presentation ACC 2024

The Effect of Edetate Disodium-based Chelation on Cardiovascular Events in Patients with a Prior Myocardial Infarction and Diabetes – Results of the TACT2 Randomized Trial

Presenter: Gervasio A. Lamas

April 07, 2024

Presentation ACC 2024

Self-Expanding Versus Balloon-Expandable TAVR in Patients with Aortic Stenosis and Small Aortic Annuli

Presenter: Howard C. Herrmann

April 07, 2024

Presentation ACC 2024

Randomized, Double-blind, Placebo-controlled, Phase 3, Study To Evaluate Lerodalcibep Long-term Efficacy And Safety In Patients With, Or At Very-high Or High Risk, For Cardiovascular Disease On Stable Lipid-lowering Therapy

Presenter: Eric Quinton Klug

April 07, 2024

Presentation ACC 2024

Principal Results From the Double-blind, Placebo-controlled ULTIMATE-DAPT Trial

Presenter: Gregg W Stone

April 07, 2024

Presentation ACC 2024

Primary Results from the Phase 2 KARDIA-2 Study

Presenter: Akshay Desai

April 07, 2024

Presentation ACC 2024

PREVENT: Preventive PCI versus Medical Therapy Alone for Treatment of Vulnerable Atherosclerotic Coronary Plaques

Presenter: Seung-Jung Park

April 07, 2024

Presentation ACC 2024

Percutaneous Transvalvular Micro axial Flow Pump in Infarct Related Cardiogenic Shock

Presenter: Jacob Eifer Møller

April 07, 2024

Presentation ACC 2024

Gamification, Financial Incentives, or Both to Increase Physical Activity Among Patients at High Risk of Cardiovascular Events: The BE ACTIVE Randomized Controlled Trial

Presenter: Alexander Fanaroff

April 07, 2024

Presentation ACC 2024

Bridge-TIMI 73a: Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk

Presenter: Brian Bergmark

April 07, 2024

News Conference News ACC 2024

SMART: Small Aortic Annuli May Fare Best With Self-Expandable Valve

L.A. McKeown

April 07, 2024

News Conference News ACC 2024

Long-Awaited RCT Data Show Survival Benefit With Impella CP: DanGer Shock

Caitlin E. Cox

April 07, 2024

News Conference News ACC 2024

EDTA Chelation No Help in Cutting CV Outcomes After MI in Diabetic Patients: TACT2

Shelley Wood

April 07, 2024

News Conference News ACC 2024

Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute MI

Michael O'Riordan

April 07, 2024

News Conference News ACC 2024

Oral Device Noninferior to CPAP for Reducing BP in Sleep Apnea: CRESCENT

Caitlin E. Cox

April 06, 2024

News Conference News ACC 2024

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

L.A. McKeown

April 06, 2024

News Conference News ACC 2024

Full AEGIS-II Results: Raising HDL With Apo A-I No Help After Acute MI

Yael L. Maxwell

April 06, 2024

Advertisement

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Comparison of IVUS-guided vs. Angiography-guided Angioplasty for the Outcomes of DCB in the Treatment of Femoropopliteal Artery Disease

A Selective Aldose Reductase Inhibitor for the Treatment of Diabetic Cardiomyopathy

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

The Effect of Edetate Disodium-based Chelation on Cardiovascular Events in Patients with a Prior Myocardial Infarction and Diabetes – Results of the TACT2 Randomized Trial

Self-Expanding Versus Balloon-Expandable TAVR in Patients with Aortic Stenosis and Small Aortic Annuli

Randomized, Double-blind, Placebo-controlled, Phase 3, Study To Evaluate Lerodalcibep Long-term Efficacy And Safety In Patients With, Or At Very-high Or High Risk, For Cardiovascular Disease On Stable Lipid-lowering Therapy

Principal Results From the Double-blind, Placebo-controlled ULTIMATE-DAPT Trial

Primary Results from the Phase 2 KARDIA-2 Study

PREVENT: Preventive PCI versus Medical Therapy Alone for Treatment of Vulnerable Atherosclerotic Coronary Plaques

Percutaneous Transvalvular Micro axial Flow Pump in Infarct Related Cardiogenic Shock

Gamification, Financial Incentives, or Both to Increase Physical Activity Among Patients at High Risk of Cardiovascular Events: The BE ACTIVE Randomized Controlled Trial

Bridge-TIMI 73a: Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk

SMART: Small Aortic Annuli May Fare Best With Self-Expandable Valve

Long-Awaited RCT Data Show Survival Benefit With Impella CP: DanGer Shock

EDTA Chelation No Help in Cutting CV Outcomes After MI in Diabetic Patients: TACT2

Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute MI

Oral Device Noninferior to CPAP for Reducing BP in Sleep Apnea: CRESCENT

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

Full AEGIS-II Results: Raising HDL With Apo A-I No Help After Acute MI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content